Health-related quality of life (HRQoL) assessment with once- and twice-daily darunavir/ritonavir (DRV/r) in the ODIN trial by Spinosa-Guzman, S et al.
POSTER PRESENTATION Open Access
Health-related quality of life (HRQoL) assessment
with once- and twice-daily darunavir/ritonavir
(DRV/r) in the ODIN trial
S Spinosa-Guzman
1*, T Van de Casteele
1, G De La Rosa
2, P De Doncker
1
From Tenth International Congress on Drug Therapy in HIV Infection
Glasgow, UK. 7-11 November 2010
Background
The open-label, Phase III, ODIN trial randomised treat-
ment-experienced HIV-1-infected patients with no DRV
resistance-associated mutations (RAMs) to receive DRV/
r 800/100mg qd or DRV/r 600/100mg bid, plus an opti-
mised background regimen (≥2N R T I s ) .N o n - i n f e r i o r i t y
in the primary endpoint of virological response at Week
48 was demonstrated with DRV/r qd versus bid dosing:
72.1% vs 70.9% of patients, respectively, achieved HIV-1
RNA <50 copies/mL (95% CI: -6.1, 8.5; p<0.001; ITT-
TLOVR). The current analysis explores patient-reported
HRQoL.
Methods
Treatment-experienced patients with no DRV RAMs at
screening and HIV-1 RNA >1,000 copies/mL were ran-
domised. Patient-reported HRQoL was measured with
the Functional Assessment of HIV-infection (FAHI)
questionnaire at baseline and at Weeks 4, 12, 24 and 48
(or withdrawal visit). FAHI score at Week 48 was mod-
elled by means of an ANCOVA, and the evolution of
the FAHI score over time by means of a longitudinal
mixed model, each with treatment as a factor and CD4
and baseline HIV-1 RNA as a regressor. FAHI response
was defined as the proportion of patients with a clini-
cally meaningful difference (relative increase of 10%) in
total FAHI imputed score versus baseline.
Results
HRQoL data were available for 262/294 DRV/r qd and
268/296 DRV/r bid patients. The baseline total FAHI
imputed score was relatively high (124.1 and 121.2 for
DRV/r qd and bid, respectively), leaving limited room
for improvement. Mean (SE) increase in total FAHI
score from baseline (ITT-LOCF) at Week 48 was com-
parable with DRV/r qd and bid dosing (table 1). A mean
increase in total FAHI score from baseline was observed
in both treatment groups at all timepoints. No relevant
between-group differences were noted either by
ANCOVA (p=0.761) or longitudinal mixed model
(p=0.995). There were no relevant differences between
arms at any time in the proportion of FAHI responders
(p=0.957).
Conclusions
DRV/r qd and bid dosing was comparable with respect
to the increase in mean total FAHI score from baseline
at Week 48 and in the proportion of patients achieving
a clinically meaningful difference in total FAHI score at
Week 48.
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Table 1
DRV/r 800/
100mg qd
(n=262)
DRV/r 600/
100mg bid
(n=268)
Mean (SE) change in total FAHI
score from baseline (ITT-LOCF)
Baseline value 124.1 (1.78) 121.2 (1.73)
Week 4 0.4 (1.10) 1.3 (1.08)
Week 12 3.2 (1.18) 1.7 (1.28)
Week 24 2.8 (1.27) 2.5 (1.26)
Week 48 2.7 (1.36) 3.1 (1.40)
FAHI responders (LOCF) at Week
48, %
27.5 29.5
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